5. Curis ( CRIS) researches and develops cancer therapeutics. Collaborator Genentech just initiated a Phase II trial of GDC-0449. Curis's second-quarter loss decreased 50% to $2.1 million, or 3 cents a share, as revenue expanded 57%. Curis has $45 million of cash and no debt. Its stock trades at a book value multiple of 2.1 and a sales multiple of 7.1, 61% and 93% discounts to industry averages. All five analysts covering Curis recommend that clients purchase its shares. A median price target of $3.75 suggests that the stock will rally 164%.

Bullish Scenario: RBC ( RY) forecasts that Curis's stock will appreciate 182% to $4.

If you liked this article you might like

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Next Year's Stock Returns: 5% or 15%?

Next Year's Stock Returns: 5% or 15%?

Updating a Small Speculative Play

Updating a Small Speculative Play

Three Large-Cap Growth Stocks

Three Large-Cap Growth Stocks